The aim of the present study was to characterize patterns of use of methylphenidate (MPH), a prescription stimulant medication recommended in the treatment of attention deficit hyperactivity disorder (ADHD) and of narcolepsy, in France, both in children and adults, over a 3-year period.
Introduction
Since 2000, the dispensing of methylphenidate (MPH), a prescription stimulant medication commonly used in the treatment of attention deficit hyperactivity disorder (ADHD), has significantly increased worldwide in children and adults [1] [2] [3] [4] [5] [6] [7] [8] , the concern actually are for efficacy and safety of the long term use for all the users (principally for young people where MPH is authorized in ADHD; and the use for young children (<6 years) and adults for whom MPH isn't authorized (only for narcolepsy in adults). To established and assess the patterns of this increase, numerous studies have been performed across a wide range of countries, with the aim of estimating the prevalence of MPH use and associated factors (European countries [2, 5, 6, 8, [10] [11] [12] [15] [16] [17] [18] , United States [3, 13, 14] , and Australia [14] ).
National guidelines for initiating drug therapy in children or adolescents to treat ADHD have been based on solid evidence from short-term studies, without addressing the major concern about the long-term use of, treatment adherence with, and the misuse or inappropriate use of MPH. Improved diagnosis of ADHD among children may explain this huge increase throughout the world. Studies in children have focused on establishing the increase in psychotropic drug use over time, and characterizing its patterns of use (regular, occasional or short-term) [14, [18] [19] [20] . Other studies have focused on patients with ADHD, irrespective of their age (adults and/or children) [3, [20] [21] [22] [23] [24] [25] , with the aim of characterizing treatment initiation and persistence.
For adults, the increase in MPH use may be linked to improved diagnosis of ADHD in this population,for whom prevalence rates of ADHD have been established varying between 1% and 7% in a metaanalysis [26] . Nevertheless, there remains uncertainty concerning the diagnosis of ADHD, and the long-term efficacy and safety of MPH in this adult population. In relation to the duration of MPH use for the adult population, precedent studies that have been carried out specifically in Nordic countries, where the increase in, and amount of MPH use have been an important concern [12, 20, 27] , found short treatment durations and/or early treatment discontinuations [20] but with discrepancies throughout distinct age groups [11, 27] . Other important concerns are related to the possible use of MPH for medical conditions other than ADHD, such as Parkinson's disease [28] or bipolar depression [29] , or in patients with cognitive slowing [30] [31] [32] or substance use disorder (SUD) [1, 29, 33, 34] .
Despite a large amount of literature on the topic, our overall understanding of patterns of MPH use is sparse due to the variation in the populations analysed in the different studies.
Indeed, some studies have focused only on children, others only on adults and others only on patients diagnosed with ADHD. Nevertheless, the concerns are from one study to another, even if the studied outcomes are not exactly the same, the overall concern converge to the description of different patterns of use like coprescription of other drugs, including psychotropic medications, and drug abuse. Taken alone, these studies are informative and give a clear comprehension of the different patterns which resumes profiles of MPH users considering the different patterns of use as a whole, at least in France.
To our knowledge, few pharmacoepidemiological studies have focused both on children and adults. A recent study in Denmark found an overuse of other psychotropic medications, an increase in dose and differences in the duration of treatment between children and adults [11] . This study was carried out on prevalent users, thus preventing any characterization of MPH use at its initiation -in particular, the specialty of the prescribing physician -and of the concomitant use of other medications at the time of its initiation.
We sought to assess patterns of MPH use both in children and adult incident users over a 3-year period according to distinct age groups, using a unique data source, and according to characteristics both at initiation and during follow-up, such as: the quantities dispensed, time between refills, treatment duration, concomitant use of other drugs (6 months before initiation and during follow-up), polypharmacy and multiple prescribers.
Methods

Database
This was a retrospective observational cohort study based on data from the French general health insurance drug database [General Health Insurance System (GHIS)] in two regions of the south of France (Provence-Alpes-Côte-d'Azur and Corsica) over a 4-year-period (2010-2013). The GHIS is the main national health insurance fund in France and covers employed and unemployed people and students, which corresponds to about 87% of the entire French population (self-employed people and farmers are covered by other specific funds). In 2011, these two regions included 4 147 748 individuals covered by the GHIS. Drug prescription claims are automatically recorded in a database by the pharmacists and transmitted online to the GHIS. According the French legislation on privacy, patient, prescriber and pharmacy identifiers are unique anonymous numbers.
Population selected
From the GHIS database, we first included patients with GHIS coverage who had MPH dispensed (ATC code: N06BA04) at least once from 1 July 2010 to 30 June 2013. The starting date of inclusion was chosen so as to include only incident patients -i.e. patients with no dispensing of MPH over the 6-month period before the screening period, which was took place from 1 January 2010 to 30 June 2010. The end of the inclusion period was chosen so as to ensure at least 6 months of follow-up for people included in 2013. We performed a sensitivity analysis, using a threshold of 1 year to analyse the impact of a different definition of incident user to the characteristisation of the population.
The only ADHD drug marketed in France is MPH, which is marketed for patients aged ≥6 years who are affected by ADHD [35] . Two MPH formulations are available: one immediate-release (IR) (Ritalin ®) and several extendedrelease (ER) (Ritalin®, Quasym®, Concerta® and Medikinet®) formulations. In adults, MPH is licensed as a second-line treatment in narcolepsy when modafinil has been found to lack efficacy (only for Ritalin 10 mg ®), and only one (Concerta ®) of the extended-release formulations has been licensed in adult ADHD in cases where it has been efficacious during childhood, but cannot be started in adults. According to narcotic substance legislation in France, MPH is subject to restrictive conditions of prescription and delivery: initiation in hospitals must be by neurologists, psychiatrists or paediatricians; prescription is limited to a 28-day period and valid for 1 year; refill of the prescription can be authorized by any other physician for a maximum period of 1 year but it must be for the same dose and frequency as initially prescribed.
Collection of data
The following variables relevant to the study were extracted: age, gender, chronic disease, student system of healthcare reimbursement, prescriber and type of prescriber (general practitioner, practice specialist or hospital physician), date of dispensing, pharmacy identifier code, drug name, drug code and quantity delivered. Drugs were categorized according to the Anatomical Therapeutic Chemical (ATC) classification [antidepressants (ATC: N06A), benzodiazepines (ATC: N05BA, N05CD; N03AE01 for clonazepam), opiate maintenance treatments, including methadone and high-dose buprenorphine (N07 BC), opioid analgesics (N02A), antipsychotic agents (N05A) and modafinil (N06BA07)]. The total quantities of drugs dispensed were expressed in defined daily doses (DDD) according to the World Health Organization Collaborating Centre for Drug Statistics Methodology [36] ; for MPH, one DDD corresponds to 30 mg.
Data analysis
We defined age categories according the following thresholds: children under 6 years of age, children (6-11 years of age), adolescents (12-17 years of age), young adults (18-24 years of age), adults (25-49 years of age) and adults over 50 years of age.
Firstly, we established the profiles of MPH incident users stratified by age group. We then focused on patients with more than one dispensing of MPH, and followed up these patients. We were particularly interested in collecting information on concomitant use of other medications, specifically central nervous system (CNS) drugs (opioid analgesics, benzodiazepines, antipsychotic agents); the time between two dispensings; and the dose dispensed. We defined concomitant use of medication as at least one dispensing of another drug between the first and last dispensing of MPH, irrespective of the prescribing physician. We defined the dose dispensed as the quantity of drug dispensed (in mg) divided by the time until the next dispensing. Use of other CNS drugs was assessed over two periods: during the 6 months preceding the initiation with MPH and during the entire follow-up. This allowed us to get an indication of the proportion of patients stopping or continuing use of these other medications during MPH treatment. All of the dispensings between the inclusion of the patient until the end of their follow-up (last MPH dispensing or 31 December 2013) were included. As our objective was to create a descriptive and exhaustive overview, all patients, including outliers (such as those with a high number of dispensings) were analysed.
Retention rates and Kaplan-Meier drug survival plots
For patients with at least two dispensings, we then computed retention rates of MPH and the median duration of treatment, with a threshold of 90 days as the maximum time allowed between two dispensings. For each patient, the duration of treatment was calculated as the time between the first and the last prescription occurring before a gap of at least 90 days until the next dispensing. For this sub-analysis, treatment was considered as terminated when 90 days had passed without the individual filling a prescription for MPH, and the date of 31 December 2013 was the censoring date. The long interval (90 days) allowed between prescriptions was chosen to avoid assigning a false treatment termination date for patients who had long intervals between prescriptions. We illustrated this using Kaplan-Meier drug-survival plots. Sensitivity analyses using two different time intervals (45 days and 365 days) between two dispensings were performed.
Results
Population included
Overall, we included 3534 incident users between 1 July 2010 and 30 June 2013 (see Figure 1 ). Considering the annual number of people affiliated to the GHIS, the estimated annual number of incident users increased from 27/100 000 people in 2011 to 29/100 000 people in 2013 (an increase of 7%).
These incident MPH users were aged from 1 year to 91 years, with 2335 (66%) children and 1199 (34%) adults. Profiles of incident users according to age groups are presented in Table 1, dispensing characteristics in Table 2 , and the Kaplan-Meier plots for drug survival are presented in Figure 2 . Among the children, we observed a predominance of boys, with a gender ratio (boys/girls) of 2, while for adults the gender ratio was 1. The proportion of patients with chronic disease (available only for adults) was higher with increasing age (23% for 18-24-year-olds, 46% for 25-49-year-olds and 61% for ≥50 year-olds). Among the incident patients, 2621 (75%) reported at least two dispensings of MPH but this proportion tended to decrease with increasing age, from 74% for the youngest children to 45% for the oldest adults. Among these incident users, there were 113 students, 88% of whom were aged between 18 and 24 years; the others were aged between 25 and 49 years.
We then established patterns of MPH use for the 2621 patients dispensed MPH at least twice. For children, the treatment was mostly initiated in a hospital by a specialist (neurologist, paediatrician or psychiatrist), while for adults initiation was mostly shared between the general practitioner and the hospital physician. Overall, the formulation of the first dispensing of MPH differed according to age: the IR form at initiation was more often used for the 1-5 year old children (47%) and for ≥50 -year-old adults (46%) than for the four other age groups for whom the percentage of IR form at initiation varies between 23% to 33%.
The median number of different physicians visited by patients varied between the different age groups, between two (for 12-17 ; 18-24 and ≥50 year-old patients) and three (for ≤6; 6-11 and 25-49 year-olds patients). The duration of follow-up (time between the first and last dispensing), and median drug survival and retention rates (with 90 days allowed between two dispensings) decreased with age: 6-month retention rates ranged from 78% for 1-5-year-old children to 42% for ≥50-year-old adults. The Kaplan-Meier plot for drug survival ( Figure 2) shows that children initiating treatment before the age of 12 years had a higher treatment retention rate, which persisted over time.
Dose computing (quantity dispensed divided by the duration between two dispensings) showed that the mean and median dose increased with age, with the highest values for 25-49-year-old adults, for whom the median dose was 89.6 
Association with other CNS medications
Medication dispensed during the 6-month period prior to MPH initiation and during MPH treatment is shown in Table 3 , and details of the top three medications codispensed during follow-up are presented in Table 4 . For children less than 6 years of age, 14% were prescribed an antipsychotic drug concomitantly with their MPH treatment. The majority of these treatments were introduced at least 6 months before MPH initiation. Four children (4.7%) had codeine prescribed concomitantly.
For children aged 6-11 and 12-17 years, 8% were prescribed an antipsychotic drug (mostly risperidone) concomitantly with their MPH treatment, and this was mainly introduced at least 6 months before MPH treatment. About 6% were prescribed an anxiolytic agent (mostly hydroxyzine) other than a benzodiazepine (BZD). For young adults (18-24 years of age), about 21% were prescribed BZDs concomitantly, and 19% antidepressants. These treatments were mainly prescribed at least 6 months before MPH initiation.
Patients aged 25-49 years were characterized by higher concomitant use of other CNS drugs. Indeed, 67% were coprescribed BZDs, 40% antidepressants, 39% opioid analgesics, 35% antipsychotic agents and 32% opiate maintenance treatments (high-dosage buprenorphine for 23% and methadone for 13%).
Patients ≥50 years of age were also characterized by concomitant use of CNS drugs such as BZDs (62%), but more specifically presented the highest concomitant use of antidepressants (58%) and antiparkinsonian medications (26%), which were already in use before the MPH initiation.
For adults, even though MPH is indicated for the secondline treatment of narcolepsy in cases where modafinil has been found to lack efficacy, only a minority were prescribed modafinil 6 months before MPH initiation: between 2% and 3% for adults under 50 years of age, and 12% for those ≥50 years of age.
Discussion
The present study provides a detailed overview of MPH initiation and use both in children and adults over a 3-year period in a geographical area in the south of France covering more than 4 million individuals (those covered by the GHIS). The use of MPH increased during the study period (an increase of 7% in the number of incident users between 2010 and 2013), although remained at a lower number in 2013 (29/100 000 inhabitants) than in other European countries [2, 12] (0.3 defined daily dose /1000 inhab/day in France in 2012 vs. 4.53 ddd/1000 inhab/day in the Netherlands as an example). Yet, the prevalence of ADHD has been estimated (using self-reports) as being higher in France (1.7%) than in other European countries (1.6% in the Netherlands, for example [29] ). Moreover, a recent study carried out in the same geographical area as used in the present study [37] found that the use of MPH has increased in the past few years by 135% in children and 343% in adult populations, in a context where the use of MPH is already higher in children than in adults [7] . The current pharmacoepidemiological study is rare because it established the characteristics of new users of MPH, irrespective of age, over a 3-year period, and included dose, duration, concomitant use of other medication, visits to multiple prescribers and the number of dispensings in multiple pharmacies. Thus, evaluation of different age groups revealed that the huge increase in MPH use these over the past few years can have multiple causes. The present analysis demonstrated that the pattern of use for children is consistent with guidelines, with regular visits to physicians, adequate doses and a long duration of treatment. Patterns of use are different for adults, as multiple profiles for adults seem to emerge, and one of them the 25-49 year olds suggest abusive behaviors.
Children had characteristically higher retention rates and less concomitant use of other psychotropic medication than adults. For children, the mean duration of treatment was longer for those initiating MPH therapy at a young age (6-11 years), while the highest dropout rate after one dispensing was observed for 1-5-year-old children (27%). Use of MPH for these preschool children has not been approved and is controversial due to the lack of pertinent data about its safety on the developing brain of these children, and on its efficacy in this population [38] . One-quarter of these preschool children dropped out after one prescription. This may have been the consequence of adverse events [39, 40] or of uncertainty about the diagnosis, but as such data were not available in our database, we could not state this definitively.
Adults represented 34% of incident MPH users, although this agent is not recommended for this population (only one of the ER formulations, Concerta®, is authorized for adult patients for continuation of an effective treatment of ADHD during childhood, and Ritalin® 10 mg for narcolepsy in cases where modafinil has lacked efficacy). Modafinil is rarely prescribed before MPH initiation, leading us to hypothesize that a small proportion of these patients are prescribed MPH for narcolepsy. Compared with children, among whom boys were predominant in terms of MPH use, this gender ratio tended towards 1 after young adulthood, in accordance with studies demonstrating that although boys are more commonly diagnosed with ADHD than girls, when diagnosed for ADHD in young adulthood, women and men are equally likely to be diagnosed [26, 33] .
Patterns of MPH use for adults seem to differ according to their age group. The characteristics of 18-24-year-old patients were found to be similar to those for 12-17-year-old patients, with regular visits to their physician, which may prove the hypothesis that some ADHD patients are diagnosed later, in young adulthood [26] . However, they took more comedications (in particular BZDs) and had a lower median drug survival (5.5 months), and the fact that 42% of them were students led us hypothesize that this might reflect misuse by non-ADHD students, to boost their academic performance and/or induce euphoria (party, social enhancement) [41, 42] . However, we cannot disentangle these hypotheses, and it would be particularly interesting to compare patterns of MPH use between students and others in future research.
The 25-49-year-old group differed from the other adults. Firstly, this group was characterized by lower retention rates, with almost half having used MPH only once. Moreover, for patients with multiple dispensings, we observed higher quantities dispensed, a higher number of different physicians and/or pharmacies visited, less time between two dispensings and higher rates of concomitant use of other psychoactive drugs, with BZDs being the most frequently used. These observed characteristics may illustrate distinct behaviours of MPH misuse related to comorbid psychiatric disorders and SUD. Our first hypothesis is that MPH is used by adults with ADHD who have SUD or another psychiatric disorder concomitantly. Indeed, this 25-49-year-old group had a higher prevalence of use of antidepressants, antipsychotic agents and opioid maintenance treatment (OMT) prior to MPH initiation, which has already been observed in other studies [14, 17] , and these other medications may be used to treat these comorbidities. The prevalence of comorbid psychiatric disorders in this age group, particularly depression, anxiety, mood and SUD [34, [43] [44] [45] is high, which also makes diagnosis and treatment challenging. Moreover, this raises concerns about the safety and impact of MPH on comorbid mental health problems associated with ADHD in adults, and the literature on this topic is controversial [20, 44, 46, 47] . It is possible that the higher dropout rate (46%) after one dispensing in 25-49-year-old patients is due to side effects related to these other comorbidities after the first administration of MPH. In particular, MPH is contraindicated for some psychiatric comorbidities, such as severe depression, psychotic symptoms, severe mood disorders, mania, schizophrenia and psychopathic/borderline personality disorders. It would have been interesting to analyse medications introduced after the discontinuation of MPH treatment. Concerning patients with SUD in particular, it has been demonstrated that ADHD is highly prevalent in treatment-seeking patients with an SUD (23.1% in a recent meta-analysis [48] ) and that SUD patients required higher doses of MPH [49] . In our 25-49-year-old group, we observed higher doses of MPH Table 3 Associated dispensing during the follow-up and 6 months before methylphenidate (MPH) initiation (patients with >1 dispensing of methylphenidate by pharmaceutical class)
Children under 6 years old Table 4 Top three concomitant drugs dispensed for each pharmaceutical class and age group (incident users, n = 2621) 
(24%)
Risperidone, n = 11, 13% Risperidone, n = 90, 7%
Risperidone, n = 28, 5%
Lithium, n = 9, 6%
Olanzapine, n = 54, 12%
Lithium, n = 9, 12%
Cyamemazine, n = 3, 4% Cyamemazine, n = 15, 1%
Cyamemazine, n = 8, 2%
Cyamemazine, n = 6, 4%
Lithium, n = 46, 10% Cyamemazine, Olanzapine, Quetiapine, n = 5, 7%
Tiapride, n = 1, 1%
Pimozide, n = 1, 0.2% Risperidone, n = 5, 3%
Aripiprazole, n = 44, 10%
Opioids analgesics 4 (5%)
43 (3%) 30 (6%) 18 (12%) 173 (39%)
(26%)
Codeine, n = 4, 5%
Codeine, n = 36, 3%
Tramadol, n = 19, 4% Morphine sulphate, n = 10, 7%
Morphine sulphate, n = 98, 22%
Tramadol, n = 12, 16%
Tramadol n = 9, 1% Codeine, n = 11, 2%
Tramadol, n = 6, 4%
Tramadol, n = 89, 20%
Morphine sulphate, n = 7, 9%
Codeine, n = 5, 3%
Codeine, n = 41, 9%
Codeine, n = 5, 7%
Anxiolytic and hypnotic agents other than BZDs High-dose buprenorphine, n = 3, 4%
High-dose buprenorphine,
Methadone, n = 58, 13%
Methadone, n = 2, 3%
BZD, benzodiazepines
Patterns of use of methylphenidate and also a higher percentage of OMT. The literature concerning MPH treatment for OMT patients is scarce, and conclusions concerning evidence for the benefits of treatment with ADHD drugs in patients with SUD have been divergent [46, 47, [50] [51] [52] . It is also possible that a high proportion of patients drop out after one dispensing because of a lack of efficacy of MPH. Yet, even if MPH medications could be effective in treating ADHD in patients with SUD, close monitoring would be necessary to ensure that these stimulants are used in a therapeutic manner and to see how MPH ultimately affects, or not, the patient's SUD [46] . These considerations on MPH use for patients suffering from SUD are related to the potential for abuse associated with this drug. The second hypothesis concerning these particular characteristics of MPH use in the 25-49-year-old group is related to the possible use of MPH by patients who did not have ADHD but suffered from SUD and may have been abusing MPH [53] . The potential for abuse and addiction to this drug, which is increasingly misused, has now been clearly established, and some of the characteristics observed in the population studied here may have been related to particular behaviours linked to drug abuse. Indeed, in this subpopulation, a non-negligible proportion of adults resorted to the IR formulation, which has already been linked to diversion [1] . They also used flunitrazepam (24%) or morphine sulphate (22%), which are both potential drugs of abuse [54, 55] , and visited a larger number of different physicians, reinforcing the hypothesis of a possible diversion of MPH by 'doctor shopping', which consists of obtaining overlapping prescriptions by two or more prescribers [56] . This behaviour has, in particular, already been characterized in the PACA-Corse region (the same geographical region as investigated in our study), with an estimated increase of 6% in the overall quantities of MPH obtained by diversion through doctor shopping in 2011 [1] . The abuse of MPH has also been reported in other countries [57] [58] [59] , with people using it as a cognitive enhancer and/or for recreational purposes [1, 42, [58] [59] [60] [61] [62] [63] , particularly in association with the intravenous route of administration [1, 59, 64] . In a recent study carried out in France in subjects abusing MPH [1] , a few patients reported a history of ADHD and some of them reported using other CNS drugs concomitantly with MPH, to manage symptoms during 'comedown', such as anxiety, tiredness, paranoia, feeling sick or depression. The growing availability of the drug due to its increasing use for medical purposes may be a factor influencing its abuse by non-ADHD patients. Indeed, the availability of prescription drugs has been demonstrated to be linked to the nonmedical use and abuse of these medications with abuse potential [65, 66] . There have been serious concerns about the relationship between the increase in the consumption of stimulants (including MPH) in the USA and a possible diversion [67] . Increased clinician awareness is essential in helping to reduce prescription drug abuse, while continuing to provide effective treatment. The results observed in the older adult group (>50 years) suggested that they consumed MPH for a shorter period of time (median drug survival 3.4 months) and had a poorer health status (61% were affected by a chronic disease, the nature of which was unknown to us). The fact that they had high rates of comedication with other CNS drugs (mostly BZDs and antidepressants), large increases in BZD use after MPH initiation, and the highest rate of use of antiparkinsonian medications (26%) raises questions about the medical context of MPH use. Indeed, this may be related to experimental MPH use for a variety of diseases (depressive symptoms, fatigue, apathy), as an adjuvant to narcotic analgesics and for cognitive slowing in populations such as medically ill older adults and patients receiving palliative care, as previously described in the literature [30, 32, 61, 62] .
The present study had some limitations. As we used a medico-administrative database, clinical data were not available to cross-refer to information on the indication for MPH, the severity of the illness, or socioeconomic factors (such as educational levels, with the exception of the student status, depending on the student reimbursement plan). Yet, all of these factors have been proved to be linked to the persistence of MPH use for ADHD, contributing to the effectiveness of this drug for this condition [68] . In our study, in which the persistence of MPH use was measured throughout the duration of treatment, until its first interruption (with 90 days allowed between two dispensings), the results were consistent with those from another study from northern Europe [20] , involving young users (and a longer duration of treatment). Sensitivity analyses extending the interval allowed between prescription fillings to 365 days, or reducing it to 45 days, provided the same conclusions, but with different values for median drug survival (see Table S1 ). For this analysis of treatment retention, only the first treatment episode for each person was included -i.e. a person refilling a prescription after more than 90 days of interruption was not reintroduced into the analysis. Another perspective would be to analyse multiple sequences of MPH treatment per patient, involving different doses and comedications. In our study, we could not determine the reasons why patients interrupted their treatment, as we did not have access to a hospitalization database to investigate acute adverse events, and did not know if any patients died. Such studies will be done, using the exhaustive database linking hospitalizations, deaths and the dispensing of medications throughout the whole of France.
Another limitation was that the database we used did not include the entire French population, but only inhabitants of a French region in the south of France who were covered by the GHIS, so we could not consider the results to be fully representative for the whole of France. Nevertheless, we estimated that there were 27 new users per 100 000 people in 2010, and an analysis on another French sample estimated 21 incident users per 100 000 people [69] , which was reasonably similar. Moreover, self-employed people were not included into the present study, and we do not know if these patients tends to consume more or less MPH. We defined incident patients as those with no dispensings of MPH during a previous six-month period. A sensitivity analysis using a threshold of 1 year with no previous dispensings of MPH provided the same results (Table S2) . Nevertheless, further investigation is needed to quantify the proportion of adults considered as incident MPH users who had already been prescribed MPH during childhood.
In conclusion, MPH use in France has increased both in young and adult patients, although the prevalence of MPH use seems to be lower in France compared with that in other European countries and in north America. We have demonstrated different patterns of use across age groups, highlighting long-term use for children, use in medical conditions other than ADHD for adults and possible drug abuse/misuse behaviours, in particular for 25-49-year-old patients. These different patterns imply that various strategies are needed, in order to minimize the risk of adverse events, in particular in older people, and also the risk of abuse.
